Fig. 4.

Pharmacokinetic characterisation and ChIP analysis. The pharmacokinetic behaviour of trabectedin was investigated in ML017 and ML017/ET (a). Drug levels were slightly higher in the resistant than the sensitive models. Plasma and liver had similar trabectedin concentrations (ANOVA followed by Bonferroni post hoc test, **p < 0.01, * p < 0.05). ChIP assay was used to examine the binding of FUS-CHOP on FN-1 promoter (b): the binding of the chimeric protein decreased after trabectedin in the sensitive model but remained stable in the resistant one